A Quantitative Study of US FDA Inspection Data for Drug Manufacturing Sites

  • Ajay Babu PazhayattilEmail author
  • Marzena Ingram
  • Naheed Sayeed
Review Article


The purpose of this study was to determine if any correlations could be identified from the form 483 observations issued by the US FDA during routine GMP inspections of drug substance and drug product manufacturing sites. The data analysed encompassed inspection observations from 2014 through 2018. The intent of the study is to provide unbiased insight to regulatory trends and to understand any underlying factors that may contribute to a sites non-compliance status. The data sets utilized in this study was derived from the US FDA public information database: Inspection Classification Database which was part of a 2009 open government initiative. The inspection observation data sets are ones that has been classified. The study results provide insights into domestic and foreign inspection trends. The assessment of 2014–2018 form 483 observations from FDA database revealed that the number of 483 forms issued has been on the increase however the number of observations has declined.


FDA 483 Inspection trend Establishment inspection report Official Action Indicated GMP 




Compliance with Ethical Standards

Conflict of interest

All authors declare that they have no conflict of interest.


  1. 1.
    Hamburg MA. Justification of estimates for appropriations committees fiscal year 2016. Rockville: Department of Health and Human Sciences, FDA; 2016.Google Scholar
  2. 2.
    FDA. Integration of FDA facility evaluation and inspection program for human drugs: A concept of operations. Rockville: Center for Drug Evaluation and Research; 2017.Google Scholar
  3. 3.
    FDA. Transparency initiative: draft proposals for public comment to increase transparency by promoting greater access to the agency’s compliance and enforcement. Washington: Data Transparency Task Force, US Department of Health and Human Services; 2011.Google Scholar
  4. 4.
    Federal Register. Title 21: Part 210, 211: current good manufacturing practice. Washington: Code of Federal Regulations; 2011.Google Scholar
  5. 5.
    Lawton G. Choosing the best visualization tools for big data analytics. Newton: TechTarget; 2018.Google Scholar
  6. 6.
    Hodgson D, Maini F, Greenrose W, Christiani S, Chan S, Hargitai B. Under the spotlight: Data integrity in life sciences. London: Deloitte; 2017.Google Scholar
  7. 7.
    Higgins BK. Inspection trends. Richmond: American Society for Quality; 2016.Google Scholar
  8. 8.
    Unger, B. (2018). FY2017 FDA drug inspection observations and trends, Life Science Connect.Google Scholar

Copyright information

© The Drug Information Association, Inc 2019

Authors and Affiliations

  • Ajay Babu Pazhayattil
    • 1
    Email author
  • Marzena Ingram
    • 2
  • Naheed Sayeed
    • 3
  1. 1.WellandCanada
  2. 2.Eurofins Alphora Research Inc.TorontoCanada
  3. 3.Sanofi PasteurTorontoCanada

Personalised recommendations